These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29277178)

  • 1. [Clinical Significance and Mechanism of PI3K p110β Overexpression
 in Non-small Cell Lung Cancer].
    Xiong Y; Qu L; Li D; Wang Y; Li T
    Zhongguo Fei Ai Za Zhi; 2017 Dec; 20(12):808-816. PubMed ID: 29277178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance and mechanism of upregulation of PI3Kp110α in non-small cell lung carcinoma].
    Xiong Y; Qu LL; Li D; Wang Y; Li T
    Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):737-743. PubMed ID: 29061016
    [No Abstract]   [Full Text] [Related]  

  • 3. [Expression and significance of PTEN/PI3K signal transduction-related proteins in non-small cell lung cancer].
    Liao DW; Wang L; Zhang XG; Liu MQ
    Ai Zheng; 2006 Oct; 25(10):1238-42. PubMed ID: 17059767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.
    Karlsson T; Krakstad C; Tangen IL; Hoivik EA; Pollock PM; Salvesen HB; Lewis AE
    Oncotarget; 2017 Jan; 8(3):3881-3894. PubMed ID: 28002804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological significance of PTEN and PI3K/AKT signal transduction pathway in non-small cell lung cancer.
    Yun F; Jia Y; Li X; Yuan L; Sun Q; Yu H; Shi L; Yuan H
    Int J Clin Exp Pathol; 2013; 6(10):2112-20. PubMed ID: 24133589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.
    Tang JM; He QY; Guo RX; Chang XJ
    Lung Cancer; 2006 Feb; 51(2):181-91. PubMed ID: 16324768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.
    Pazarentzos E; Giannikopoulos P; Hrustanovic G; St John J; Olivas VR; Gubens MA; Balassanian R; Weissman J; Polkinghorn W; Bivona TG
    Oncogene; 2016 Mar; 35(9):1198-205. PubMed ID: 25982275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CB/p110β is a selective survival factor for glioblastoma.
    Pridham KJ; Le L; Guo S; Varghese RT; Algino S; Liang Y; Fajardin R; Rodgers CM; Simonds GR; Kelly DF; Sheng Z
    Neuro Oncol; 2018 Mar; 20(4):494-505. PubMed ID: 29016844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of HER2 and PTEN simultaneous deregulation in non-small cell lung carcinoma: correlation with biological behavior.
    Panagiotou I; Georgiannos SN; Tsiambas E; Karameris A; Konstantinou M; Lazaris AC; Kavantzas N; Vilaras G; Patsouris E
    Asian Pac J Cancer Prev; 2012; 13(12):6311-8. PubMed ID: 23464451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-101-3p inhibits the growth and metastasis of non-small cell lung cancer through blocking PI3K/AKT signal pathway by targeting MALAT-1.
    Zhang X; He X; Liu Y; Zhang H; Chen H; Guo S; Liang Y
    Biomed Pharmacother; 2017 Sep; 93():1065-1073. PubMed ID: 28738500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
    Utermark T; Schmit F; Lee SH; Gao X; Schaffhausen BS; Roberts TM
    J Virol; 2014 Sep; 88(18):10673-9. PubMed ID: 24991009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly expressed long non-coding RNA CRNDE promotes cell proliferation through PI3K/AKT signalling in non-small cell lung carcinoma.
    Liu XX; Xiong HP; Huang JS; Qi K; Xu JJ
    Clin Exp Pharmacol Physiol; 2017 Aug; 44(8):895-902. PubMed ID: 28477368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MKRN2 inhibits migration and invasion of non-small-cell lung cancer by negatively regulating the PI3K/Akt pathway.
    Jiang J; Xu Y; Ren H; Wudu M; Wang Q; Song X; Su H; Jiang X; Jiang L; Qiu X
    J Exp Clin Cancer Res; 2018 Aug; 37(1):189. PubMed ID: 30103781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
    Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
    Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Akt1/IL-6/STAT3 pathway regulates growth of lung tumor initiating cells.
    Malanga D; De Marco C; Guerriero I; Colelli F; Rinaldo N; Scrima M; Mirante T; De Vitis C; Zoppoli P; Ceccarelli M; Riccardi M; Ravo M; Weisz A; Federico A; Franco R; Rocco G; Mancini R; Rizzuto A; Gulletta E; Ciliberto G; Viglietto G
    Oncotarget; 2015 Dec; 6(40):42667-86. PubMed ID: 26486080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms.
    Lee HJ; Seol HS; Kim JY; Chun SM; Suh YA; Park YS; Kim SW; Choi CM; Park SI; Kim DK; Kim YH; Jang SJ
    Ann Surg Oncol; 2013 Jan; 20(1):200-8. PubMed ID: 22915320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of M3 muscarinic receptor by acetylcholine promotes non-small cell lung cancer cell proliferation and invasion via EGFR/PI3K/AKT pathway.
    Xu R; Shang C; Zhao J; Han Y; Liu J; Chen K; Shi W
    Tumour Biol; 2015 Jun; 36(6):4091-100. PubMed ID: 25964092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.